CMSC: Investigational Frexalimab Reduces T1 Lesions in Relapsing Multiple Sclerosis
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Nursing, Medicine, Healthcare Management, Pharmacy
Neurology
price
Free
CMSC: Investigational Frexalimab Reduces T1 Lesions in Relapsing Multiple Sclerosis is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jun 07, 2023
Termination Date: Jun 06, 2024
Activity Goal:
The goal of this program is to provide data from medical meetings, expert analysis insights on current and emerging management strategies, and interactive case studies based on the most up-to-date evidence-based medicine and clinical trial results in MS.
Learning Objective(s):
• Appraise recent clinical efficacy and safety evidence for available and emerging DMTs for MS management.